Anemia como fator preditivo negativo de resposta ao tratamento do câncer de colo uterino / Anemia as a negative predictive factor for response to treatment of cervical cancer

Luciano de Souza Viana, Harley Francisco de Oliveira, Henrique Hott Fernandes, Isabela de Sousa Martins, Larissa de Araújo Franco, Lígia Machea Duarte, Natália Quintão Barros

Abstract


Introdução: No Brasil, o câncer cervical (CC) é o terceiro tumor maligno mais frequente nas mulheres e a quarta causa de morte por câncer entre a população feminina, de acordo com o Instituto Nacional do Câncer (INCA). O agrupamento TNM, o tipo e grau histológico, a invasão linfovascular e/ou perineural são fatores prognósticos independentes, assim como a anemia. Objetivos: O presente estudo analisou o risco de óbito no primeiro ano de seguimento oncológico após término da radioterapia, conforme nível de hemoglobina (HB) pré tratamento (<10g/dl vs ≥10g/dl). Método: Estudo tipo coorte retrospectiva que incluiu pacientes com diagnóstico de CC, admitidas e tratadas em centro especializado de oncologia de Ipatinga - MG, Brasil no período de 2014 a 2017. Resultados: Pacientes com HB ≥ 10g/dl no pós tratamento apresentaram menor chance de evoluir para o óbito com relação às pacientes com HB < 10g/dl. 66,1% dos pacientes com HB ≥ 10g/dl no baseline foram classificados como livre da doença após término da radioterapia. O valor da HB após término da radioterapia também foi preditivo de resposta à radioterapia. Conclusão: A presença de HB < 10g/dl após término do tratamento correlacionou-se negativamente com tipo de resposta e risco de óbito.

Keywords


Câncer de colo do útero, Baixa hemoglobina, Prognóstico, Radioterapia.

References


BISHOP, A. J., et al. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: Has the impact of anemia been overstated? International Journal of Radiation Oncology Biology Physics, 2015. 91(1), 196-205.

CAO, Wei et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal, v. 134, n. 7, p. 783, 2021.

DUNST J, et al. Anemia in cervical cancers; impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003; 56: 778–87.

FYLES A.W., et al. Anemia, hypoxia and transfusion in patients with cervical cancer: A review. Radiother Oncol 2000; 57: 13–9.

GILLIAN, Thomas; ALI,Shamshad; HOEBERS, J P, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108(2):317-325. doi:10.1016/j.ygyno.2007.10.011.

GROGAN M. et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528–36.

INCA. Instituto Nacional do Câncer. Tipos de câncer: câncer do colo uterino. 2021.

KRYSTYNA S., ANDRZEJ B. & JACEK J. Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy, Acta Oncologica, 2006. 45:6, 695-701.

KOULIS, A. T. et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study. Clin Transl Radiat Oncol. 2017. 12: 51-56.

MARANGA IO, et al. Analysis of Factors Contributing to the Low Survival of Cervical Cancer Patients Undergoing Radiotherapy in Kenya. PLoS ONE 2013. 8(10): e78411.

MINISTÉRIO DA SAÚDE. Saúde amplia vacinação contra HPV para mulheres imunossuprimidas com até 45 anos. 2021 . Disponível em: . Acesso em: 23 de setembro, 2021.

ROFSTAD EK, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastases. Br J Cancer 2000; 83: 354–9.

SHIN, N. et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstetrics & Gynecology Science. 2014. 1: 28-36.

SUNG, Hyuna et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, v. 71, n. 3, p. 209-249, 2021.

VIAS, P. et al. A prospective study comparing hemoglobin levels and response in patients of locally advanced carcinoma cervix receiving accelerated chemoradiation versus conventional chemoradiation. Journal of radiation and cancer research. 2019. 3 (10): 135-140.

WORLD HEALTH ORGANIZATION. Clinical Transfusion Practice Guidelines for Medical Interns. 2 ed. Bangladesh: World Health Organization; 2020. 42p.

WORLD HEALTH ORGANIZATION. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2 ed. Geneva: World Health Organization; 2021. 97p

YADDANAPUDI, S; YADDANAPUDI, LN. Indications for blood and blood product transfusion. Indian J Anaesth. 2014. 58 (5): 538-542.

YANAZUME, S. et al. Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy. Jpn J Clin Oncol. 2018. 48: 892-899.




DOI: https://doi.org/10.34117/bjdv7n12-047

Refbacks

  • There are currently no refbacks.